Newron bags €40m EIB loan

The loan will provide Newron with financial flexibility beyond 2019. The company’s product safinamide is the first New Chemical Entity in a decade approved in Europe and the U.S. for the treatment of Parkinson’s disease (PD). Newron has two advanced product candidates in late stage clinical development: Sarizotan for the treatment of respiratory disturbances in Rett syndrome, which is evaluated in the ongoing potentially pivotal STARS  study, and Evenamide as a symptomatic add-on therapy to clozapine for the treatment of schizophrenia. 

Newron plans to directly market orphan drugs emerging of its clinical pipeline. EIB financing is intended to boost Newron’s R&D activities and will primarily be used to support the Company’s pivotal and post approval stage development programmes.

Newron has a strong pipeline of treatments for rare disease patients at various stages of clinical development, including Sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.